EDEN PRAIRIE, MINN. — May 4, 2026 — Leads & Copy — NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) has received notification from Nasdaq that it has regained compliance with Nasdaq Marketplace Rule 5550(a)(2), concerning minimum bid price requirements. The matter is now closed.
NeuroOne had previously been notified on May 6, 2025, that its common stock’s closing bid price had fallen below the required $1 per share for continued listing on the Nasdaq Capital Market. An extension was granted on November 4, 2025, giving the company until May 4, 2026, to regain compliance.
To address this, NeuroOne executed a 1-for-6 reverse stock split, effective April 15, 2026. Trading began on a split-adjusted basis on April 16, 2026. The company’s common stock continues to trade on Nasdaq under the symbol “NMTC” but now trades under a new CUSIP Number, 64130M308.
NeuroOne Medical Technologies Corporation focuses on improving surgical care options for patients with neurological disorders. It markets a minimally invasive electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions aim to reduce hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. The Company is engaged in research and development for drug delivery, basivertebral nerve ablation and spinal cord stimulation programs.
Source: NeuroOne Medical Technologies Corporation
